Seoulin Bioscience Co.,Ltd. Statistics

Total Valuation

Seoulin Bioscience Co.,Ltd. has a market cap or net worth of KRW 62.43 billion. The enterprise value is 38.89 billion.

Market Cap	62.43B
Enterprise Value	38.89B

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Seoulin Bioscience Co.,Ltd. has 8.55 million shares outstanding. The number of shares has decreased by -10.76% in one year.

Shares Outstanding	8.55M
Shares Change (YoY)	-10.76%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	29.90%
Owned by Institutions (%)	0.47%
Float	6.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.74
PB Ratio	0.75
P/FCF Ratio	14.62
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.70, with an EV/FCF ratio of 9.11.

EV / Earnings	-65.85
EV / Sales	0.46
EV / EBITDA	13.70
EV / EBIT	26.63
EV / FCF	9.11

Financial Position

The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.03.

Current Ratio	3.92
Quick Ratio	2.34
Debt / Equity	0.03
Debt / EBITDA	0.88
Debt / FCF	0.57
Interest Coverage	0.96

Financial Efficiency

Return on equity (ROE) is -3.32% and return on invested capital (ROIC) is 0.89%.

Return on Equity (ROE)	-3.32%
Return on Assets (ROA)	0.73%
Return on Capital (ROIC)	0.89%
Revenue Per Employee	812.64M
Profits Per Employee	-5.68M
Employee Count	104
Asset Turnover	0.70
Inventory Turnover	2.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.38%
50-Day Moving Average	7,996.20
200-Day Moving Average	8,825.39
Relative Strength Index (RSI)	33.43
Average Volume (20 Days)	28,315

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoulin Bioscience Co.,Ltd. had revenue of KRW 84.51 billion and -590.62 million in losses. Loss per share was -69.00.

Revenue	84.51B
Gross Profit	18.69B
Operating Income	1.41B
Pretax Income	-2.42B
Net Income	-590.62M
EBITDA	2.78B
EBIT	1.41B
Loss Per Share	-69.00

Full Income Statement

Balance Sheet

The company has 27.98 billion in cash and 2.45 billion in debt, giving a net cash position of 25.54 billion or 2,986.08 per share.

Cash & Cash Equivalents	27.98B
Total Debt	2.45B
Net Cash	25.54B
Net Cash Per Share	2,986.08
Equity (Book Value)	85.58B
Book Value Per Share	9,772.82
Working Capital	46.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.68 billion and capital expenditures -412.86 million, giving a free cash flow of 4.27 billion.

Operating Cash Flow	4.68B
Capital Expenditures	-412.86M
Free Cash Flow	4.27B
FCF Per Share	499.43

Full Cash Flow Statement

Margins

Gross margin is 22.11%, with operating and profit margins of 1.66% and -0.70%.

Gross Margin	22.11%
Operating Margin	1.66%
Pretax Margin	-2.87%
Profit Margin	-0.70%
EBITDA Margin	3.29%
EBIT Margin	1.66%
FCF Margin	5.05%

Dividends & Yields

This stock pays an annual dividend of 97.66, which amounts to a dividend yield of 1.34%.

Dividend Per Share	97.66
Dividend Yield	1.34%
Dividend Growth (YoY)	-21.24%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	10.76%
Shareholder Yield	12.10%
Earnings Yield	-0.95%
FCF Yield	6.84%

Dividend Details

Stock Splits

The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.0239188.

Last Split Date	Dec 27, 2023
Split Type	Forward
Split Ratio	1.0239188

Scores

Seoulin Bioscience Co.,Ltd. has an Altman Z-Score of 5.1.

Altman Z-Score	5.1
Piotroski F-Score	n/a